Mark Socinski, MD, introduces a panel of medical experts as they kick off a discussion surrounding biomarker testing and guideline recommendations in the metastatic non-small cell lung cancer treatment landscape.
Optimizing Care for Metastatic Non-Small Cell Lung Cancer Without Driver Mutations
Key opinion leaders provide insight to providing biomarker testing within and beyond guideline recommendations.
A panel of experts discuss the current limitations of optimal biomarker testing rates in the community.
A panel of experts discuss the importance of up-front biomarker testing.
A panel of experts describe the key challenges and unmet needs for patients with newly diagnosed mNSCLC.
A panel of experts discuss how the NCCN guideline recommendations differ for patients with and without PD-L1 expression.
The panel of experts in lung cancer examines genetic alterations affecting treatment response and biomarker testing rates in metastatic non-small cell lung cancer (mNSCLC).
Key opinion leaders explore molecular characteristics beyond mutations that influence immunotherapy response in non small cell lung cancer treatment.
A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.
The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.
The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.
Advertisement
Advertisement
